Reversal agents for non-vitamin K antagonist oral anticoagulants

被引：0
|
作者：
Jerrold H. Levy
James Douketis
Jeffrey I. Weitz
机构：
[1] Critical Care,Department of Anesthesiology
[2] and Surgery,Department of Medicine
[3] Duke University Medical Center,undefined
[4] 2301 Erwin Road,undefined
[5] 5691H HAFS,undefined
[6] Box 3094,undefined
[7] Durham,undefined
[8] North Carolina 27710,undefined
[9] USA.,undefined
[10] McMaster University,undefined
[11] Thrombosis and Atherosclerosis Research Institute,undefined
来源：
Nature Reviews Cardiology | 2018年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit factor XaThree NOAC reversal agents are in various stages of development: idarucizumab is licensed in many countries, andexanet is under consideration by regulatory agencies, and ciraparantag is undergoing phase III evaluationIdarucizumab is approved for dabigatran reversal in patients requiring emergency surgery or urgent procedures and in those with life-threatening or uncontrolled bleedingIn the absence of licensed reversal agents for the oral factor Xa inhibitors, prothrombin complex concentrates are increasingly used in patients taking these agents who present with life-threatening bleeding
引用
收藏
页码：273 / 281
页数：8
相关论文
共 50 条
  • [1] Reversal agents for non-vitamin K antagonist oral anticoagulants
    Levy, Jerrold H.
    Douketis, James
    Weitz, Jeffrey I.
    [J]. NATURE REVIEWS CARDIOLOGY, 2018, 15 (05) : 273 - 281
  • [2] Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents
    Ruff, Christian T.
    Giugliano, Robert P.
    Antman, Elliott M.
    [J]. CIRCULATION, 2016, 134 (03) : 248 - 261
  • [3] Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants
    Andresen, Kristoffer
    Atar, Dan
    Gjertsen, Erik
    Ghanima, Waleed
    Roseth, Svein
    Johansen, Odd Erik
    [J]. SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2018, 52 (03) : 156 - 162
  • [4] Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?
    Washam, Jeffrey B.
    Piccini, Jonathan P.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (02) : 279 - 284
  • [5] Non-vitamin K antagonist oral anticoagulants and sport
    Romano, Silvio
    Salustri, Elisa
    Robles, Antonio G.
    Calo, Leonardo
    Penco, Maria
    Sciarra, Luigi
    [J]. MINERVA CARDIOANGIOLOGICA, 2020, 68 (02): : 98 - 109
  • [6] Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal
    Sujan T. Reddy
    TC Cossey
    Sean I. Savitz
    James C. Grotta
    [J]. Current Neurology and Neuroscience Reports, 2017, 17
  • [7] Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?
    Jeffrey B. Washam
    Jonathan P. Piccini
    [J]. Journal of Thrombosis and Thrombolysis, 2016, 41 : 279 - 284
  • [8] Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal
    Reddy, Sujan T.
    Cossey, T. C.
    Savitz, Sean I.
    Grotta, James C.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (09)
  • [9] Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
    Enriquez, Andres
    Lip, Gregory Y. H.
    Baranchuk, Adrian
    [J]. EUROPACE, 2016, 18 (07): : 955 - 964
  • [10] Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
    Malagu, Michele
    Longo, Filomena
    Marchini, Federico
    Sirugo, Paolo
    Capanni, Andrea
    Clo, Stefano
    Mari, Elisa
    Culcasi, Martina
    Bertini, Matteo
    [J]. BIOLOGY-BASEL, 2023, 12 (04):
12345